Morningstar (MORN) Insider Sales: Joseph Mansueto Disposes 21,750 Shares
Rhea-AI Filing Summary
Morningstar, Inc. (MORN) Executive Chairman Joseph D. Mansueto reported multiple sales of Common Stock under a Rule 10b5-1 trading plan adopted November 15, 2024. The Form 4 shows eight sale transactions executed August 15, 18 and 19, 2025, totaling 21,750 shares disposed of at reported weighted-average prices ranging approximately from $258.03 to $261.035. Following those transactions the filing shows the reporting person directly beneficially owns 9,340,231 shares and indirectly beneficially owns 5,336,106 shares held by grantor retained annuity trusts plus 150,000 shares held in trusts for the benefit of his children. The filing notes the sales were effected pursuant to the 10b5-1 plan and provides ranges of execution prices for each grouped trade.
Positive
- Sales conducted under a Rule 10b5-1 trading plan, indicating pre-established execution and compliance with trading rules
- Detailed disclosure of post-transaction beneficial ownership including direct and indirect holdings and trustee roles
- Commitment to provide full execution details upon request, enhancing transparency about trade prices and quantities
Negative
- Executive Chairman sold 21,750 shares in August 2025, which is an insider disposition disclosed to the market
- Multiple sales over consecutive days may prompt investor questions about timing, though filed as 10b5-1 transactions
Insights
TL;DR Executive Chairman sold 21,750 shares under a pre-established 10b5-1 plan; remaining direct and indirect holdings remain substantial.
The Form 4 reveals structured disposition activity: eight sell transactions on August 15, 18 and 19, 2025, executed under a Rule 10b5-1 plan adopted November 15, 2024. The filings disclose weighted-average sale prices for grouped trades and state the precise post-transaction beneficial ownership totals: 9,340,231 shares directly and 5,486,106 shares indirectly via trusts. From an investor-analysis perspective, the record shows compliance with an established plan and transparency on execution price ranges, but it does not include any company performance data or reasons for the trust holdings and dispositions.
TL;DR Transactions were executed under a documented 10b5-1 plan and the filer disclosed trust ownership and trustee roles.
The report documents that the sales were made pursuant to a 10b5-1 trading plan, which provides an affirmative defense under Rule 10b5-1 when conditions are met. The filing also discloses the nature of indirect holdings: grantor retained annuity trusts for the reporting person and trusts for his children, and identifies trustees. The Form 4 includes undertaking language offering to supply detailed execution data upon request, supporting transparency. The filing does not allege any change in officer or director status.